Joseph Thome

Laura Chico

Ryan Deschner

Louise Chen

Aydin Huseynov

Christopher Raymond

Dennis Ding

Prakhar Agrawal

Roanna Clarissa Ruiz

Yuchen Ding

Allison Bratzel

Ashleigh Acker

John Kim

Matthew Kaplan

Thomas Yip

Yigal Nochomovitz

- Ardelyx reported **total revenue of $110.3 million** for Q3 2025, marking a **12% increase** compared to Q3 2024.  **[0001437402_2218242_5]**  This was driven by **IBSRELA revenue of $78.2 million**, a **92% increase** year-over-year, and **XPHOZAH revenue of $27.4 million**, a **9% increase** compared to Q2 2025.  **[0001437402_2218242_1]** **[0001437402_2218242_3]** **[0001437402_2218242_4]** **[0001437402_2218242_5]** 
- The company raised its full-year guidance for IBSRELA revenue to between **$270 million and $275 million**.  **[0001437402_2218242_1]** **[0001437402_2218242_5]** 
- Ardelyx announced **RDX 10531 (531)**, a next-generation NHE3 inhibitor, as its first new development program in over three years, with preclinical and manufacturing activities underway for a Phase I study.  **[0001437402_2218242_1]** 
- The company concluded Q3 2025 with a strong balance sheet, including **$242.7 million in cash, cash equivalents, and short-term investments**, and reported a net loss of approximately **$1 million**.  **[0001437402_2218242_5]**  **Suhong Leitner** was also welcomed as the new Chief Financial Officer.  **[0001437402_2218242_2]** **[0001437402_2218242_5]**

Ardelyx Reports Strong Q3 2025 Results, Raises IBSRELA Guidance, and Announces New Pipeline Asset

- Ardelyx reported **Q3 2025 total revenue of $110.3 million**  **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:1]** , with **IBSRELA revenue of $78.2 million**  **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:0]** **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:1]** , which grew **92% year-over-year**  **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:0]** , and **XPHOZAH revenue of $27.4 million**  **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:0]** **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:1]** , up 9% from Q2 2025.  **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:0]** 
- The company raised its **IBSRELA full-year 2025 revenue guidance to between $270 million and $275 million**.  **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:0]** 
- Ardelyx announced the development of **RDX10531**, a next-generation NHE3 inhibitor, with an Investigational New Drug (IND) submission planned for 2026.  **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:0]** 
- The company ended Q3 2025 with **$242.7 million in cash, cash equivalents, and short-term investments**  **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:1]**  and reported a **net loss of $1.0 million**.  **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:1]** 
- **Sue Hohenleitner was appointed as Chief Financial Officer**, effective November 4, 2025.  **[1437402_0001437402-25-000016_ardx-20250930xexhibit991.htm:1]**

Ardelyx Reports Q3 2025 Financial Results and Raises IBSRELA Guidance

- Ardelyx is highly confident in its two main products, projecting **Ibsrela** to reach **$1 billion** in sales and **Exposa** to reach **$750 million**.  **[1437402_tx_379074_0]** **[1437402_tx_379074_2]** 
- The company raised its full-year guidance for **Ibsrela** from **$240 million-$250 million** to **$250 million-$260 million**.  **[1437402_tx_379074_4]** 
- **Exposa** has shown month-over-month prescription growth since February, with positive Q2 signs in new and refill prescriptions, as the company focuses on the **220,000-patient non-Medicare market**.  **[1437402_tx_379074_0]** **[1437402_tx_379074_5]** 
- A hearing for Ardelyx's legal challenge against CMS regarding the TDAPA rule is scheduled for **September 25** in district court.  **[1437402_tx_379074_7]** 
- The company indicates that profitability and breakeven are not far in the distant horizon.  **[1437402_tx_379074_8]**

Ardelyx Provides Updates on Product Momentum, Raised Guidance, and Legal Proceedings

ARDELYX (ARDX)